I. Monreal-Santesteban

CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer

M. Esteller, D. Megías, D. Escors, 2017, Oncotarget.

Differential role of gene hypermethylation in adenocarcinomas, squamous cell carcinomas and cervical intraepithelial lesions of the uterine cervix

R. Guarch, D. Escors, E. Martín-Sánchez, 2015, Pathology international.

Gene promoter hypermethylation is found in sentinel lymph nodes of breast cancer patients, in samples identified as positive by one-step nucleic acid amplification of cytokeratin 19 mRNA

D. Escors, A. Córdoba, E. Martín-Sánchez, 2016, Virchows Archiv.

A DNA Methylation-Based Gene Signature Can Predict Triple-Negative Breast Cancer Diagnosis

A. Córdoba Iturriagagoitia, E. Martín-Sánchez, S. Mendaza, 2021, Biomedicines.

ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer

A. Córdoba, R. Beloqui, E. Martín-Sánchez, 2020, International journal of molecular sciences.

CDH22 hypermethylation is an independent prognostic biomarker in breast cancer

A. Córdoba, E. Martín-Sánchez, S. Mendaza, 2017, Clinical Epigenetics.

ZEB1 hypermethylation is associated with better prognosis in patients with colon cancer

I. Monreal-Santesteban, D. Guerrero‐Setas, Irene Fernandez-De-Los-Reyes, 2023, Clinical epigenetics.